F-18 fluciclovine vs. Ga-68 PSMA: Which tracer is superior in metastatic breast cancer?

Monday, November 27 | 8:40 a.m.-8:50 a.m. | M1-SSNMMI02-5 | Room E350

F-18 fluciclovine PET/CT imaging results in greater metastases detection in women with invasive lobular carcinoma (ILC) of the breast than gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-PET/CT, while both are superior to conventional imaging, according to this presentation.

Presenter Aliza Mushtaq, MD, a postdoc research fellow at Emory University, will discuss a study comparing the use of the two PET radiotracers versus conventional imaging (CT and bone scans) in 20 women with de novo or suspected recurrent ILC.

Conventional imaging detected metastasis in five patients and in seven out of 60 regions of interest (two axillary, two extra-axillary, and three distant); Ga-68 PSMA-PET/CT detected metastasis in seven patients and in seven of 60 regions (four axillary and three distant); and F-18 fluciclovine detected metastasis in nine patients and in 13 of 60 regions (five axillary, three extra-axillary, and five distant).

In addition, F-18 fluciclovine PET was positive in all regions positive on PSMA-PET, while in six regions positive on F-18 fluciclovine, Ga-68 PSMA was negative.

“In the management of patients with ILC, novel molecular imaging, especially with F-18 fluciclovine PET-CT seems to result in greater metastases detection and deserves further study,” Mushtaq noted.

To learn all the details, check out this Monday morning session.